Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
September 12, 2023 06:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma to Participate in Upcoming September Investor Conferences
August 24, 2023 18:21 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
July 10, 2023 08:00 ET
|
Connect Biopharma Holdings Limited
Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported...
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
July 05, 2023 16:05 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, July 05, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
June 01, 2023 16:05 ET
|
Connect Biopharma Holdings Limited
Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction...
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
April 11, 2023 16:05 ET
|
Connect Biopharma Holdings Limited
CDE’s Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024 SAN DIEGO and TAICANG, SUZHOU, China, April 11, 2023 (GLOBE NEWSWIRE)...
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
February 06, 2023 08:30 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven...
Connect Biopharma Provides Business and Clinical Development Program Update
December 30, 2022 07:30 ET
|
Connect Biopharma Holdings Limited
Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of...
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
December 19, 2022 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
December 02, 2022 17:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...